Mood symptoms, neurodevelopmental traits, and their contributory factors in X-linked ichthyosis, ichthyosis vulgaris and psoriasis.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
26
01
2022
received:
03
12
2021
accepted:
27
01
2022
pubmed:
2
2
2022
medline:
7
6
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
High rates of adverse mood/neurodevelopmental traits are seen in multiple dermatological conditions, and can significantly affect patient quality of life. Understanding the sex-specific nature, magnitude, impact and basis of such traits in lesser-studied conditions like ichthyosis, is important for developing effective interventions. To quantify and compare relevant psychological traits in men with X-linked ichthyosis (XLI, n = 54) or in XLI carrier women (n = 83) and in patients with ichthyosis vulgaris (IV, men n = 23, women n = 59) or psoriasis (men n = 30, women n = 122), and to identify factors self-reported to contribute most towards depressive, anxious and irritable phenotypes. Participants recruited via relevant charities or social media completed an online survey of established questionnaires. Data were analysed by sex and skin condition, and compared with general population data. Compared with the general population, there was a higher rate of lifetime prevalence of mood disorder diagnoses across all groups and of neurodevelopmental disorder diagnoses in the XLI groups. The groups exhibited similarly significant elevations in recent mood symptoms (Cohen d statistic 0.95-1.28, P < 0.001) and neurodevelopmental traits (d = 0.31-0.91, P < 0.05) compared with general population controls, and self-reported moderate effects on quality of life and stigmatization. There were strong positive associations between neurodevelopmental traits and recent mood symptoms (r > 0.47, P < 0.01), and between feelings of stigmatization and quality of life, particularly in men. Numerous factors were identified as contributing significantly to mood symptoms in a condition or sex-specific, or condition or sex-independent, manner. We found that individuals with XLI, IV or psoriasis show higher levels of mood disorder diagnoses and symptoms than matched general population controls, and that the prevalence and severity of these is similar across conditions. We also identified a number of factors potentially conferring either general or condition-specific risk of adverse mood symptoms in the three skin conditions, which could be targeted clinically and/or through education programmes. In clinical practice, recognizing mood/neurodevelopmental problems in ichthyosis and psoriasis, and addressing the predisposing factors identified by this study should benefit the mental health of affected individuals.
Sections du résumé
BACKGROUND
BACKGROUND
High rates of adverse mood/neurodevelopmental traits are seen in multiple dermatological conditions, and can significantly affect patient quality of life. Understanding the sex-specific nature, magnitude, impact and basis of such traits in lesser-studied conditions like ichthyosis, is important for developing effective interventions.
AIM
OBJECTIVE
To quantify and compare relevant psychological traits in men with X-linked ichthyosis (XLI, n = 54) or in XLI carrier women (n = 83) and in patients with ichthyosis vulgaris (IV, men n = 23, women n = 59) or psoriasis (men n = 30, women n = 122), and to identify factors self-reported to contribute most towards depressive, anxious and irritable phenotypes.
METHODS
METHODS
Participants recruited via relevant charities or social media completed an online survey of established questionnaires. Data were analysed by sex and skin condition, and compared with general population data.
RESULTS
RESULTS
Compared with the general population, there was a higher rate of lifetime prevalence of mood disorder diagnoses across all groups and of neurodevelopmental disorder diagnoses in the XLI groups. The groups exhibited similarly significant elevations in recent mood symptoms (Cohen d statistic 0.95-1.28, P < 0.001) and neurodevelopmental traits (d = 0.31-0.91, P < 0.05) compared with general population controls, and self-reported moderate effects on quality of life and stigmatization. There were strong positive associations between neurodevelopmental traits and recent mood symptoms (r > 0.47, P < 0.01), and between feelings of stigmatization and quality of life, particularly in men. Numerous factors were identified as contributing significantly to mood symptoms in a condition or sex-specific, or condition or sex-independent, manner.
CONCLUSION
CONCLUSIONS
We found that individuals with XLI, IV or psoriasis show higher levels of mood disorder diagnoses and symptoms than matched general population controls, and that the prevalence and severity of these is similar across conditions. We also identified a number of factors potentially conferring either general or condition-specific risk of adverse mood symptoms in the three skin conditions, which could be targeted clinically and/or through education programmes. In clinical practice, recognizing mood/neurodevelopmental problems in ichthyosis and psoriasis, and addressing the predisposing factors identified by this study should benefit the mental health of affected individuals.
Identifiants
pubmed: 35104372
doi: 10.1111/ced.15116
pmc: PMC9314151
doi:
Substances chimiques
Steryl-Sulfatase
EC 3.1.6.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1097-1108Subventions
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : School of Psychology, Cardiff University
Informations de copyright
© 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Clin Med Res. 2017 Dec;15(3-4):75-87
pubmed: 29229630
PLoS One. 2012;7(2):e31500
pubmed: 22347487
Aust N Z J Psychiatry. 2011 Apr;45(4):308-16
pubmed: 21332432
J Affect Disord. 2021 Mar 1;282:426-433
pubmed: 33422818
Int J Dermatol. 2016 Sep;55(9):939-55
pubmed: 27009931
Front Neuroendocrinol. 2014 Aug;35(3):320-30
pubmed: 24887405
J Am Acad Dermatol. 2010 Jul;63(1):114-23
pubmed: 19944485
Dermatopathology (Basel). 2021 May 07;8(2):107-123
pubmed: 34066992
J Am Acad Dermatol. 2020 Sep;83(3):951-954
pubmed: 32006604
J Cutan Med Surg. 2021 May-Jun;25(3):257-270
pubmed: 33263264
Lancet Psychiatry. 2017 Apr;4(4):339-346
pubmed: 27979720
Neurosci Biobehav Rev. 2015 Aug;55:322-32
pubmed: 25981892
PLoS One. 2019 Feb 15;14(2):e0212330
pubmed: 30768640
Dermatol Ther. 2021 Jan;34(1):e14628
pubmed: 33277959
Br J Dermatol. 2017 Oct;177(4):1052-1059
pubmed: 28314054
Autoimmun Rev. 2014 Apr-May;13(4-5):490-5
pubmed: 24434359
Int J Dermatol. 2019 Jan;58(1):3-23
pubmed: 29917231
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Dermatologica. 1978;157(4):238-44
pubmed: 357213
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
Int J Dermatol. 2022 Jul;61(7):783-791
pubmed: 34403497
J Child Psychol Psychiatry. 2019 Aug;60(8):866-874
pubmed: 30908655
Exp Dermatol. 2019 Oct;28(10):1156-1163
pubmed: 29672931
Br J Dermatol. 2021 Apr;184(4):627-637
pubmed: 32531800
Clin Exp Dermatol. 2020 Dec;45(8):1106-1108
pubmed: 32975849
JAMA Dermatol. 2013 Oct;149(10):1173-9
pubmed: 23925466
Br J Dermatol. 2013 Jun;168(6):1155-66
pubmed: 23301728
Pediatr Dermatol. 2010 Mar-Apr;27(2):148-53
pubmed: 20537064
Dermatol Ther. 2020 Nov;33(6):e13827
pubmed: 32543743
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):23-38
pubmed: 28833648
Psychol Med. 2010 Feb;40(2):225-37
pubmed: 19531277
Cutis. 2018 Nov;102(5S):21-25
pubmed: 30566553
Arch Gen Psychiatry. 2011 May;68(5):459-65
pubmed: 21536975
J Dermatolog Treat. 2014 Apr;25(2):115-8
pubmed: 23030461
J Am Acad Dermatol. 2017 Mar;76(3):393-403
pubmed: 28212760
Assessment. 2015 Feb;22(1):101-15
pubmed: 24830513
J Atten Disord. 2021 Apr;25(6):771-782
pubmed: 31189421
J Am Acad Dermatol. 2010 Mar;62(3):480-5
pubmed: 20080321
Br J Dermatol. 2018 Oct;179(4):933-939
pubmed: 29901853
J Autism Dev Disord. 2019 Feb;49(2):773-780
pubmed: 30244391
Nat Sci Sleep. 2012 May 29;4:73-80
pubmed: 23620680
J Invest Dermatol. 2015 Apr;135(4):984-991
pubmed: 25521458
Neurosci Biobehav Rev. 2017 Mar;74(Pt A):139-148
pubmed: 28111269
PLoS One. 2016 Oct 6;11(10):e0164417
pubmed: 27711218
Br J Dermatol. 2012 Mar;166(3):646-8
pubmed: 22014001
Brain Behav Immun. 2015 May;46:232-6
pubmed: 25681541
J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):202-212.e7
pubmed: 22265366
Orphanet J Rare Dis. 2016 Nov 9;11(1):151
pubmed: 27829465
Nat Methods. 2014 Feb;11(2):121-2
pubmed: 24481215
Body Image. 2016 Dec;19:175-185
pubmed: 27768987
J Affect Disord. 2018 Oct 1;238:458-464
pubmed: 29929155
J Med Genet. 2020 Oct;57(10):692-698
pubmed: 32139392
Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151
pubmed: 31034875
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795